Purple Biotech Ltd (PPBT) — Cash Flow-to-Debt Ratio
Purple Biotech Ltd (PPBT) has a Cash Flow-to-Debt Ratio of -0.17x as of September 2025, meaning its operating cash flow of ILA-1.07 Million could theoretically repay 0% of its total liabilities (ILA6.25 Million) in one year. See PPBT working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Purple Biotech Ltd Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Purple Biotech Ltd across 8 annual periods. Also explore Purple Biotech Ltd (PPBT) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Purple Biotech Ltd (2017–2024)
Year-by-year debt coverage analysis for Purple Biotech Ltd. For market capitalisation and broader financial context, see market cap of Purple Biotech Ltd.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.48x | ILA-14.37 Million | ILA4.13 Million | ▼ -74.8% |
| 2023 | -1.99x | ILA-19.93 Million | ILA10.01 Million | ▲ +10.5% |
| 2022 | -2.22x | ILA-16.73 Million | ILA7.52 Million | ▲ +25.7% |
| 2021 | -3.00x | ILA-15.25 Million | ILA5.09 Million | ▼ -0.3% |
| 2020 | -2.98x | ILA-12.09 Million | ILA4.05 Million | ▼ -106.4% |
| 2019 | -1.45x | ILA-5.58 Million | ILA3.86 Million | ▲ +36.6% |
| 2018 | -2.28x | ILA-8.48 Million | ILA3.72 Million | ▼ -47.7% |
| 2017 | -1.54x | ILA-8.63 Million | ILA5.59 Million | — |